TY - JOUR
T1 - Novel Mixed NOP/Opioid Receptor Peptide Agonists
AU - Pacifico, Salvatore
AU - Albanese, Valentina
AU - Illuminati, Davide
AU - Marzola, Erika
AU - Fabbri, Martina
AU - Ferrari, Federica
AU - Holanda, Victor A.D.
AU - Sturaro, Chiara
AU - Malfacini, Davide
AU - Ruzza, Chiara
AU - Trapella, Claudio
AU - Preti, Delia
AU - Lo Cascio, Ettore
AU - Arcovito, Alessandro
AU - Della Longa, Stefano
AU - Marangoni, Martina
AU - Fattori, Davide
AU - Nassini, Romina
AU - Calò, Girolamo
AU - Guerrini, Remo
PY - 2021
Y1 - 2021
N2 - The nociceptin/orphanin FQ (N/OFQ)/N/OFQ receptor (NOP) system controls different biological functions including pain and cough reflex. Mixed NOP/opioid receptor agonists elicit similar effects to strong opioids but with reduced side effects. In this work, 31 peptides with the general sequence [Tyr/Dmt1,Xaa5]N/OFQ(1-13)-NH2 were synthesized and pharmacologically characterized for their action at human recombinant NOP/opioid receptors. The best results in terms of NOP versus mu opioid receptor potency were obtained by substituting both Tyr1 and Thr5 at the N-terminal portion of N/OFQ(1-13)-NH2 with the noncanonical amino acid Dmt. [Dmt1,5]N/OFQ(1-13)-NH2 has been identified as the most potent dual NOP/mu receptor peptide agonist so far described. Experimental data have been complemented by in silico studies to shed light on the molecular mechanisms by which the peptide binds the active form of the mu receptor. Finally, the compound exerted antitussive effects in an in vivo model of cough.
AB - The nociceptin/orphanin FQ (N/OFQ)/N/OFQ receptor (NOP) system controls different biological functions including pain and cough reflex. Mixed NOP/opioid receptor agonists elicit similar effects to strong opioids but with reduced side effects. In this work, 31 peptides with the general sequence [Tyr/Dmt1,Xaa5]N/OFQ(1-13)-NH2 were synthesized and pharmacologically characterized for their action at human recombinant NOP/opioid receptors. The best results in terms of NOP versus mu opioid receptor potency were obtained by substituting both Tyr1 and Thr5 at the N-terminal portion of N/OFQ(1-13)-NH2 with the noncanonical amino acid Dmt. [Dmt1,5]N/OFQ(1-13)-NH2 has been identified as the most potent dual NOP/mu receptor peptide agonist so far described. Experimental data have been complemented by in silico studies to shed light on the molecular mechanisms by which the peptide binds the active form of the mu receptor. Finally, the compound exerted antitussive effects in an in vivo model of cough.
KW - NOP, MOP, Nociceptin
KW - Opiod receptors
KW - NOP, MOP, Nociceptin
KW - Opiod receptors
UR - http://hdl.handle.net/10807/181205
U2 - 10.1021/acs.jmedchem.0c02062
DO - 10.1021/acs.jmedchem.0c02062
M3 - Article
SN - 1520-4804
VL - 64
SP - 6656
EP - 6669
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
ER -